Table 3.
Effect of digoxin on outcomes at the end of 2 years in systolic & diastolic heart failure (HF) patients
| Outcomes | Original data (N=7788) with 6800 SHF and 988 DHF patients |
||||
|---|---|---|---|---|---|
| Systolic HF* | Placebo (n=3403) | Digoxin (n=3397) | Absolute rate difference (%) | Hazard ratio (95% CI) | P value |
|
|
|||||
| HF hospitalization or HF mortality | 999 (29%) | 735 (22%) | − 7.8 | 0.69 (0.63–0.76) | <0.001 |
| HF hospitalization | 920 (27%) | 667 (20%) | − 7.4 | 0.68 (0.62–0.75) | <0.001 |
|
|
|||||
| Diastolic HF† | Placebo (n=496) | Digoxin (n=492) | Absolute rate difference (%) | Hazard ratio (95% CI) | P value |
|
|
|||||
| HF hospitalization or HF mortality | 90 (18%) | 67 (14%) | − 4.5 | 0.71 (0.52–0.98) | 0.034 |
| HF hospitalization | 86 (17%) | 59 (12%) | − 5.3 | 0.66 (0.47–0.91) | 0.012 |
| Matched data (N=1832) with 916 SHF and 916 DHF patients |
|||||
| Systolic HF | Placebo (n=450) | Digoxin (n=466) | Absolute rate difference (%) | Hazard ratio (95% CI) | P value |
|
|
|||||
| HF hospitalization or HF mortality | 114 (25%) | 89 (19%) | − 6.2 | 0.72 (0.55–0.95) | 0.022 |
| HF hospitalization | 102 (23%) | 80 (17%) | − 5.5 | 0.73 (0.54–0.97) | 0.033 |
|
|
|||||
| Diastolic HF | Placebo (n=460) | Digoxin (n=456) | Absolute rate difference (%) | Hazard ratio (95% CI) | P value |
|
|
|||||
| HF hospitalization or HF mortality | 86 (19%) | 62 (14%) | − 5.1 | 0.69 (0.50–0.95) | 0.025 |
| HF hospitalization | 82 (18%) | 55 (12%) | − 5.6 | 0.64 (0.45–0.90) | 0.010 |
*
Adapted from: GlaxoSmithKline. Lanoxin (digoxin) tablets, USP: Full prescribing information. 2001.
†
Adapted from: Ahmed A, et al. Circulation 2006; 114(5):397–403.